Physician profile
Dana Davis
NPI 1255330023
$887.38
in general payments reported to CMS, 2019-2025
14 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Adolescent Medicine (Internal Medicine) provider received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $28.63 · 2021: $58.92 · 2022: $15.71 · 2023: $37.11 · 2024: $253 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $381.14 | 2024-2025 | Airsupra |
| Comsort, INC | $100.00 | 2019 | |
| Pfizer INC. | $82.44 | 2023-2025 | |
| Genentech USA, INC. | $65.13 | 2019-2021 | |
| Optinose US, INC. | $58.04 | 2020-2024 | |
| Corium, LLC | $47.68 | 2025 | Azstarys |
| Lilly USA, LLC | $32.20 | 2024 | Jardiance, Zepbound |
| Astellas Pharma US INC | $24.72 | 2024 | Veozah |
| Dynavax Technologies Corporation | $20.69 | 2024 | Heplisav-B |
| Lundbeck LLC | $18.61 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.71 | 2022 | |
| Axsome Therapeutics, INC. | $14.31 | 2025 | Auvelity |
| Melinta Therapeutics, LLC | $13.55 | 2019 | |
| Inari Medical, INC. | $13.16 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.